Consensus Clene Inc.

Stocks

CLNN

US1856342019

Biotechnology & Medical Research

Market Closed - Nasdaq 06:00:00 29/09/26 am AEST			5-day change	1st Jan Change
4.060 ^USD	-5.58%		-6.67%	-30.83%

16/09	Top Midday Gainers	MT
14/08	Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Clene Inc.

Evolution of the Target Price: Clene Inc.

Changes in Analyst Recommendations: Clene Inc.

bd05956da8.yQHG6TNunNZvEY5EgZihQnMihftyQ3kUG0317PyRTTs.jGOjv1Ve96QeKO13sPzpBTZSs8MBOUtGfhqwuYrwBxa_RYOAUjTeolw82w~6029f377da2d41399b9e6d0d773a25bc

Analysts' recommendations: Clene Inc.

10/09/24	EF Hutton Initiates Clene at Buy With $23 Price Target	MT
30/06/23	Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating	MT
21/06/23	HC Wainwright Cuts Price Target on Clene to $7 From $15, Keeps Buy Rating	MT
20/06/23	EF Hutton Adjusts Clene Price Target to $10 From $13, Maintains Buy Rating	MT
16/05/23	Cantor Fitzgerald Adjusts Price Target on Clene to $4 From $5, Maintains Overweight Rating	MT
10/04/23	Benchmark Adjusts Price Target on Clene to $7 From $11, Keeps Buy Rating	MT
11/03/23	Cantor Fitzgerald Adjusts Price Target on Clene to $8 From $6, Maintains Buy Rating	MT
09/03/23	EF Hutton Starts Clene at Buy With $13 Price Target	MT
05/10/22	Oppenheimer Downgrades Clene to Perform From Outperform, Removes $17 Price Target	MT
04/10/22	Benchmark Adjusts Clene's Price Target to $11 From $25, Reiterates Buy Rating	MT
04/10/22	Canaccord Genuity Adjusts Clene's Price Target to $6 From $10, Reiterates Buy Rating	MT
17/08/22	Oppenheimer Adjusts Clene's Price Target to $17 From $16, Maintains Outperform Rating	MT
17/08/22	Cantor Fitzgerald Adjusts Clene Price Target to $12 From $10, Maintains Overweight Rating	MT
18/07/22	HC Wainwright Initiates Clene at Buy With $16 Price Target	MT
02/05/22	Canaccord Genuity Starts Clene at Buy With $10 Price Target	MT
16/02/22	Oppenheimer Adjusts Clene's Price Target to $19 From $20, Maintains Outperform Rating	MT
04/11/21	Cantor Fitzgerald Adjusts Clene's Price Target to $15 From $24, Reiterates Overweight Rating	MT
29/09/21	Clene : Oppenheimer Initiates Coverage on Clene With Outperform Rating, $20 Price Target	MT
20/05/21	Clene : Maxim Group Starts Clene at Buy With $18 Price Target	MT
03/05/21	Clene : Cantor Fitzgerald Starts Clene at Overweight With $22 Price Target	MT
03/03/21	Clene : Benchmark Starts Clene at Buy With $25 Price Target	MT
04/02/21	Clene : Roth Capital Starts Clene at Buy with $24 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CLENE INC.					+648.84%
	WUXI APPTEC CO., LTD.					+15.19%
	ARGENX SE					+22.02%
	WUXI BIOLOGICS (CAYMAN) INC.					+9.85%
	INSMED INCORPORATED					+68.92%
	BIONTECH SE					+18.94%
	GENMAB A/S					+7.76%
	PHARMAESSENTIA CORPORATION					+20.98%
	EXELIXIS, INC.					-7.69%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+32.69%
	Average					+83.75%
	Weighted average by Cap.					+21.11%